Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Cell Reports
|
June 1, 2023
Btbd11 supports cell-type-specific synaptic function
Alexei M Bygrave, Ayesha Sengupta, Ella P Jackert, et al.
Leukemia
|
May 6, 2014
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
Ellen Weisberg, Atsushi Nonami, Zhao Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2014
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R
Ellen Weisberg, Atsushi Nonami, Zhao Chen, et al.
Plos One
|
February 26, 2013
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells
Ellen Weisberg, Qingsong Liu, Xin Zhang, et al.
Annals of Surgery
|
October 8, 2013
Improving ATLS performance in simulated pediatric trauma resuscitation using a checklist
Samantha E Parsons, Elizabeth A Carter, Lauren J Waterhouse, et al.
Leukemia
|
April 4, 2012
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors
E Weisberg, Q Liu, Erik Nelson, et al.
Oncogene
|
March 20, 2021
Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer
Samantha A Hutchinson, Alex Websdale, Giorgia Cioccoloni, et al.
The American Journal of Psychiatry
|
December 6, 2012
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials
George I Papakostas, Richard C Shelton, John M Zajecka, et al.
Blood
|
September 30, 2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells
Ellen Weisberg, Johannes Roesel, Guido Bold, et al.
Molecular Cancer Therapeutics
|
July 25, 2015
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
Ellen Weisberg, Ensar Halilovic, Vesselina G Cooke, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Cell Reports
|
June 1, 2023
Btbd11 supports cell-type-specific synaptic function
Alexei M Bygrave, Ayesha Sengupta, Ella P Jackert, et al.
Leukemia
|
May 6, 2014
Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
Ellen Weisberg, Atsushi Nonami, Zhao Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2014
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R
Ellen Weisberg, Atsushi Nonami, Zhao Chen, et al.
Plos One
|
February 26, 2013
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells
Ellen Weisberg, Qingsong Liu, Xin Zhang, et al.
Annals of Surgery
|
October 8, 2013
Improving ATLS performance in simulated pediatric trauma resuscitation using a checklist
Samantha E Parsons, Elizabeth A Carter, Lauren J Waterhouse, et al.
Leukemia
|
April 4, 2012
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors
E Weisberg, Q Liu, Erik Nelson, et al.
Oncogene
|
March 20, 2021
Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer
Samantha A Hutchinson, Alex Websdale, Giorgia Cioccoloni, et al.
The American Journal of Psychiatry
|
December 6, 2012
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials
George I Papakostas, Richard C Shelton, John M Zajecka, et al.
Blood
|
September 30, 2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells
Ellen Weisberg, Johannes Roesel, Guido Bold, et al.
Molecular Cancer Therapeutics
|
July 25, 2015
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
Ellen Weisberg, Ensar Halilovic, Vesselina G Cooke, et al.
Page
of 6